3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
211
Neoplasm Metastasis
16
Neoplasms
9
Breast Neoplasms, Male
7
Breast Diseases
7
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Recurrence
2
Prostatic Neoplasms
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexuality
1
Sexual Dysfunctions, Psychological
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Primary Breast Cancer ER+ve
1
Interventions
Insulin Glargine
4
Insulin
3
volagidemab
2
Metformin
2
Fulvestrant
2
Alpelisib
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
DNA, Ribosomal
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hyperglycemia
×
exemestane
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled